

Table 3C. Asthma Treatment: Immunotherapy

Referral Guideline	Rationale	Evidence Type
<p>Consider referral for allergen immunotherapy for asthmatic patients if there is a clear relationship between asthma and exposure to an unavoidable aeroallergen to which specific IgE antibodies have been demonstrated and:</p> <ul style="list-style-type: none"> • Poor response to pharmacotherapy or avoidance measures • Unacceptable side effects of medications • Desire to avoid long term pharmacotherapy • Coexisting allergic rhinitis • Long duration of symptoms (perennial or major portion of the year) 	<p>The efficacy of allergen immunotherapy in the treatment of allergic asthma has been demonstrated in many double-blind placebo controlled studies to multiple allergens: e.g. pollen, animal allergen, fungi, dust mite.¹⁻⁴</p> <p>Referral to an asthma specialist is recommended if immunotherapy is considered.⁵</p>	<p>Indirect outcome evidence (immunotherapy)</p>
<p>Consider referral for children with allergic rhinitis because immunotherapy may potentially prevent the development of asthma</p>	<p>Allergen immunotherapy has been shown to reduce development of asthma in children with allergic rhinitis compared with group of children treated with medication alone⁶. Benefits have also been seen in adults.^{7,8} Immunotherapy may also prevent the development of new allergen sensitivities.⁹⁻¹¹</p>	<p>Indirect outcome evidence (immunotherapy)</p>

References:

1. Joint Task Force on Practice Parameters. Allergen Immunotherapy: A practice parameter second update. American Academy of Allergy, Asthma & Immunology. American College of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2007;120(3):s25-s85.
2. MJ Abramson, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of prospective, randomized double-blind, placebo-controlled studies. Am J Respir Crit Care Med 1995;151:969-974
3. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 2000; 22:329-341.
4. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma (Cochrane Review). In: *The Cochrane Library*, Issue 2 2002. Oxford: Update Software.

5. Expert Panel Report 3 (EPR3): Guidelines for the diagnosis and management of asthma – summary report 2007. *J Allergy Clin Immunol* 2007;120:s94-s138. Evidence grade: IV
6. Moller, C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). *J Allergy Clin Immunol* 2002; 109:251-256.
7. Polosa R, Li Gotti F, Mangano G, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergy rhinitis. *Allergy*. 2004;59(11):1224-8.
8. Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. *Respir Res*. 2005;6:153.
9. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. *Clin Exp Allergy* 2001; 31:1295-1302.
10. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with A Standardized Dermatophagoides Pteronyssinus Extract VI. Specific Immunotherapy Prevents The Onset of New Sensitizations In Children. *J Allergy Clin Immunol* 1997; 99:450-3.
11. Panjino GB, Barberio G, DeLuca F, Morabito L, Parmiani S. Prevention of new sensitization in asthmatic children monsensitized to house dust mites by specific immunotherapy. A six year follow-up study. *Clin Exp Allergy* 2001; 31:1392-7.